Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
4 studies found for:    "Griscelli syndrome"
Show Display Options
Download search resultsDownload the search results for:
"Griscelli syndrome" (4 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Completed
Has Results
Stem Cell Transplant for Immunologic or Histiocytic Disorders
Conditions: Hemophagocytic Lymphohistiocytosis;   X-Linked Lymphoproliferative Disorders;   Chediak-Higashi Syndrome;   Griscelli Syndrome;   Immunologic Deficiency Syndromes;   Langerhans-Cell Histiocytosis
Interventions: Procedure: Stem Cell Transplant;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Anti-thymocyte globulin (ATG);   Drug: Campath 1H;   Drug: Cyclosporin A;   Drug: Mycophenolate mofetil;   Drug: Intravenous immunoglobulin (IVIG)
2 Unknown 
Has Results
T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders
Conditions: Hemophagocytic Lymphohistiocytosis;   X-Linked Lymphoproliferative Disorders;   Chediak-Higashi Syndrome;   Griscelli Syndrome;   Immunologic Diseases;   Langerhans-Cell Histiocytosis;   Hematologic Diseases
Interventions: Procedure: Stem Cell Transplant;   Drug: Myeloablative conditioning regimen
3 Recruiting Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
Conditions: SCID;   Omenn's Syndrome;   Reticular Dysgenesis;   Wiskott-Aldrich Syndrome;   Bare Lymphocyte Syndrome;   Common Variable Immunodeficiency;   Chronic Granulomatous Disease;   CD40 Ligand Deficiency;   Hyper IgM Syndrome;   X-linked Lymphoproliferative Disease;   Hemophagocytic Lymphohistiocytosis;   Griscelli Syndrome;   Chediak-Higashi Syndrome;   Langerhan's Cell Histiocytosis
Interventions: Drug: Alemtuzumab 0.3 mg;   Drug: Cyclophosphamide;   Drug: Busulfan;   Biological: Stem Cell Transplantation;   Drug: Fludarabine phosphate 40 mg;   Drug: Melphalan;   Drug: Alemtuzumab 0.2 mg;   Drug: Fludarabine phosphate 30 mg;   Drug: MESNA
4 Completed Study of Megakaryocytes From Patients With Abnormal Platelet Vesicles
Condition: Blood Coagulation Disorders
Intervention:

Study has passed its completion date and status has not been verified in more than two years.